Infant outcomes after exposure to Tdap vaccine in pregnancy: An observational study

BMJ Open

Volumn 6, Issue 1, 2016, Pages

  Walls, Tony ^a   Graham, Patricia ^a,b   Petousis Harris, Helen ^c   Hill, Linda ^a   Austin, Nicola ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CANTERBURY DISTRICT HEALTH BOARD   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS VACCINE; VACCINE;

ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; COHORT ANALYSIS; DRUG SAFETY; FEMALE; HUMAN; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; NEW ZEALAND; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; PERTUSSIS; PRENATAL DRUG EXPOSURE; PROSPECTIVE STUDY; SIDE EFFECT; ADVERSE EFFECTS; MALE; PREGNANCY; PRENATAL CARE; VACCINATION; WHOOPING COUGH;

ADULT; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HUMANS; INFANT; MALE; NEW ZEALAND; PREGNANCY; PRENATAL CARE; PROSPECTIVE STUDIES; VACCINATION; VACCINES; WHOOPING COUGH;

EID: 84960373236     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009536     Document Type: Article

References (14)

1. Healy CM, Munoz FM, Rench MA, et al. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 2004;190:335-40.
2. Centers for Disease Control and Prevention CDC. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013;62:131-5.
3. JCVI meeting on pertussis immunisation: August 2012. https://www. gov.uk/government/groups/joint-committee-on-vaccination-andimmunisation
4. Zheteyeva YA, Moro PL, Tepper NK, et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol 2012;207:59.e1-7.
5. Munoz FM, Bond NH, Maccato M, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 2014;311:1760-9.
6. National Immunisation Register Publications. http://www.health.govt. nz/our-work/preventative-health-wellness/immunisation/nationalimmunisation-register/national-immunisation-register-publications (accessed 9 Mar 2015).
7. Munoz FM, Eckert LO, Katz MA, et al. Key terms for the assessment of the safety of vaccines in pregnancy: results of a global consultative process to initiate harmonization of adverse event definitions. Vaccine 2015;33:6441-52.
8. New Zealand Maternity Clinical Indicators. http://www.health.govt.nz/publication/new-zealand-maternity-clinical-indicators-2012 (accessed 9 Mar 2015).
9. New Zealand Birth Defects Registry. http://nzbdr.ac.nz (accessed 9 Mar 2015).
10. Grant CC, Roberts M, Scragg R, et al. Delayed immunisation and risk of pertussis in infants: unmatched case-control study. BMJ 2003;326:852-3.
11. Lindsey B, Kampmann B, Jones C. Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants. Curr Opin Infect Dis 2013;26:248-53.
12. Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014;384:1521-8.
13. Dabrera G, Amirthalingam G, Andrews N, et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and wales, 2012-2013. Clin Infect Dis 2015;60:333-7.
14. Somerville RL, Grant CC, Grimwood K, et al. Infants hospitalised with pertussis: estimating the true disease burden. J Paediatr Child Health 2007;43:617-22.